Genkyotex: Disclosure of the Total Number of Voting Rights and Shares

Pursuant to Article L. 233-8 II of the French Commercial Code and Article 223-16 of the General Regulation of the French Financial Markets Authority (AMF – Autorité des Marchés Financiers)

TOULOUSE, France & GENEVA--()--Regulatory News:

Genkyotex (Paris:GKTX) (Brussels:GKTX) :

Genkyotex shares

ISIN code FR00011790542 – Euronext Paris & Brussels

Date  

Number of shares
making up the
share capital

  Number of voting rights
March 31st, 2017   77,850,006   Theoretical number of voting rights(1): 77,850,006
    Number of voting rights exercisable at a shareholders’ meeting(2) : 77,803,008

(1) In accordance with Article 223-111 of the AMF’s General Regulation, this number of shares is calculated based on all shares carrying the right to vote, including those stripped of voting rights.

(2) Less shares stripped of voting rights.

About Genkyotex
Genkyotex is the leading biopharmaceutical company in NOX therapies. Listed on the Euronext Paris and Euronext Brussels markets, Genkyotex is established in France and, via its GenKyoTex Suisse SA subsidiary, in Switzerland. A leader in NOX therapies, its unique therapeutic approach is based on a selective inhibition of NOX enzymes that amplify multiple disease processes such as fibrosis, inflammation, pain processing, cancer development, and neurodegeneration.

Genkyotex’s platform enables the identification of orally available small-molecules that selectively inhibit specific NOX enzymes. Genkyotex is developing a pipeline of first-in-class product candidates targeting one or multiple NOX enzymes. The lead product candidate, GKT831, a NOX1 and NOX4 inhibitor is expected to enter a phase II clinical trial in primary biliary cholangitis (PBC, a fibrotic orphan disease) during the first half of 2017. This product candidate may also be active in other fibrotic indications. Its second product candidate, GKT771, is a NOX1 inhibitor targeting multiple pathways in angiogenesis, pain processing, and inflammation, and should enter a phase I clinical study during the second half of 2017.

Genkyotex also has a versatile platform, Vaxiclase, that is particularly well-suited to the development of various immunotherapies. A partnership covering the use of Vaxiclase as an antigen per se (GTL003) has been established with Serum Institute of India Ltd (Serum Institute), the world’s largest producer of vaccine doses. This agreement covers territories outside the United States and Europe, and could generate up to $57 million in revenues for Genkyotex, before royalties on sales. It will enable Serum Institute to develop acellular multivalent combination vaccines against a variety of infectious diseases, including whooping cough. The last preclinical milestone foreseen in the agreement was reached in November 2016, opening the path to formal preclinical testing prior to potential clinical development and subsequent commercialization.

For further information, please go to www.genkyotex.com

Contacts

Genkyotex

Contacts

Genkyotex